Nevertheless, our present data demonstrate that targeting CD36 in HER2 + BC may favor the transition of CSCs to a trastuzumab-sensitive state, representing an ideal combinatorial approach to boost the anti-CSC activity of trastuzumab and increase treatment efficacy in HER2 + BC patients. The gene discussed is CD36; the disease is breast cancer.